PE Tech Report


Like this article?

Sign up to our free newsletter

Regulis merges with Pharmalex

PharmaLex Group, a provider of specialised services for the pharma, biotech and medical device industries worldwide, has completed its legal merger with Regulis Consulting Limited (Regulis) in the United Kingdom, Regulis was supported by Consulting M&A throughout the transaction process.

Kim Wharton, the Founder and Managing Director of Regulis, says: “We are delighted with the support we had from CM&A. Their knowledge and expertise in corporate finance within the consulting sector helped us through the challenging moments of the process to achieve an outstanding outcome for staff, clients and shareholders.”

Regulis was founded in 2001 and is now a prominent consultancy company with vast experience of working mainly with companies specialising in pharmaceuticals, biopharmaceuticals, medical devices and cosmetics. Their team of expert pharmaceutical consultants assist in the European and Global arenas and have a strong reputation for obtaining fast, high quality regulatory approvals, as well as providing highly dependable pharmacovigilance, vigilance and GMP/GDP client solutions.

By joining forces with Regulis, PharmaLex will strengthen its already significant footprint in the UK and further increase its market share in this key market.

“The merger with PharmaLex brings significant mutual benefits”, says Wharton. “Our services in Regulatory Affairs, Pharmacovigilance and Quality Assurance align perfectly within the PharmaLex portfolio. Becoming part of a larger organisation with an excellent reputation and significant global footprint is an exciting step for Regulis h.”

“PharmaLex and Regulis joining forces offers tremendous potential to our complementary client bases and will contribute further to the successful development of our significant operations and business in the UK”, says Jon Jeffery, Head UK/Ireland Region and Managing Director, PharmaLex UK. 

“Our positive cultures and values are very well-matched and considering the strong organic growth of both businesses over recent years, expanding PharmaLex in the UK with the similarly motivated and well-regarded team at Regulis should bring further, exciting opportunities for all”, adds Dr Thomas Dobmeyer, CEO PharmaLex. 

Like this article? Sign up to our free newsletter